OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research report released on Monday. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Up 3.4 %

Shares of OPGN opened at $1.20 on Monday. The firm’s 50 day simple moving average is $1.18 and its 200 day simple moving average is $1.81. OpGen has a 1-year low of $0.53 and a 1-year high of $9.90.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.